# IntoCell

Source: https://onco.cc/companies/intocell/  
OnCo record `intocell` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IntoCell is a Korean company that develops the chemical linkers and drug payloads used to build antibody-drug conjugates, antibodies that carry a cell-killing drug to cancer cells. Its first own candidate, ITC-6146RO, entered a phase 1 trial in 2026.

## Summary

IntoCell, Inc., based in Daejeon, Korea, was founded in April 2015, according to the company history, and listed on the KOSDAQ market in May 2025. Its core technologies are the OHPAS linker, Nexatecan payload and other drug-conjugate technologies, and its history records a B7-H3 ADC research collaboration from 2017, a 2022 material transfer agreement with an option with ADC Therapeutics, a 2023 joint research agreement with Samsung Bioepis and a 2024 licence agreement with ABL Bio. ITC-6146RO received FDA clearance of its phase 1 investigational new drug application in November 2025 and Korean MFDS approval in December 2025. Its first registered cancer trial, NCT07423117, a phase 1a/b first-in-human dose-escalation and expansion study of ITC-6146RO in advanced or metastatic cancers including metastatic castration-resistant prostate cancer, non-small cell lung cancer and triple-negative breast cancer, was posted on ClinicalTrials.gov in February 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: IntoCell, Inc; 인투셀
- HQ: Daejeon
- Type: biotech
- Website: https://www.intocell.com/

## Notes

- Founding month, listing and milestones are from the company's Korean-language history page, read on 29 October 2026. The stock ticker was not stated on the pages read, so none is given. The target and payload of ITC-6146RO were not stated in the registry summary or the pages read.

## Sources

- Official website: https://www.intocell.com/
- Company history (Korean): https://intocell.com/bbs/content.php?co_id=history
- ClinicalTrials.gov: phase 1a/b trial of ITC-6146RO (NCT07423117): https://clinicaltrials.gov/study/NCT07423117

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)

---
JSON: https://onco.cc/api/v1/entities/intocell.json